loading page

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19
  • +7
  • aslı gelincik,
  • Knut Brockow,
  • Gulfem Celik,
  • Inmaculada Doña,
  • Cristobalina Mayorga,
  • A Romano,
  • Ozge Soyer,
  • Marina Atanasković-Marković,
  • Annick BARBAUD,
  • Maria Torres
aslı gelincik
Istanbul University, Istanbul Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Knut Brockow
Technical University of Munich
Author Profile
Gulfem Celik
Ankara University School of Medicine
Author Profile
Inmaculada Doña
Carlos Haya Hospital
Author Profile
Cristobalina Mayorga
IBIMA-Regional University Hospital of Malaga
Author Profile
A Romano
Presidio Columbus
Author Profile
Ozge Soyer
Hacettepe University, School of Medicine
Author Profile
Marina Atanasković-Marković
University of Belgrade, Facuty of Medicine
Author Profile
Sorbonne Universités, UPMC Univ Paris 06
Author Profile
Maria Torres
Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL
Author Profile


Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.
07 May 2020Submitted to Allergy
08 May 2020Submission Checks Completed
08 May 2020Assigned to Editor
10 May 2020Reviewer(s) Assigned
26 May 2020Review(s) Completed, Editorial Evaluation Pending
26 May 2020Editorial Decision: Revise Minor
31 May 20201st Revision Received
01 Jun 2020Submission Checks Completed
01 Jun 2020Assigned to Editor
01 Jun 2020Editorial Decision: Accept
Published in Allergy. 8 June 2020. 10.1111/all.14439